Dry eye has always been a big nuisance for surgeons. Most of the time we are dealing with fast, straightforward decisions and with procedures that lead to an immediate result, usually positive. Complications may eventually develop, but most of them are…
Omeros reported a net loss of $75.1 million, or $2.00 per share, in 2015 compared with $73.7 million, or $2.22 per share, in 2014, according to a company press release. Total costs and expenses were reported at $84.7 million in 2015 compared with $70.5…
(MedPage Today) — Health news and commentary from around the Web, gathered by the MedPage Today staff
At OSN New York, John G. Ladas, MD, PhD, FACS, discusses what he believes to be the framework for the development of a super formula for IOL calculations.
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its iStent® Trabecular Micro-Bypass Stent for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients di
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (“Aerie” or the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on March 24, dosing commenced of the first patients enrolled in Mercury 2, the Company’s second Phase 3 registration trial of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested